FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping
Medical Principles and Practice. 2014; 23 (5): 478-481
em Inglês
| IMEMR
| ID: emr-149682
ABSTRACT
To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI [5-fluorouracil, leucovorin, and irinotecan] using uridine diphosphate glucuronosyl transferase [UGT1A1] genotyping.Clinical Presentation and Intervention A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Camptotecina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Leucovorina
/
Glucuronosiltransferase
/
Anticorpos Monoclonais Humanizados
/
Técnicas de Genotipagem
/
Fluoruracila
/
Hiperbilirrubinemia
/
Metástase Neoplásica
Tipo de estudo:
Relato de Casos
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Med. Princ. Pract.
Ano de publicação:
2014
Similares
MEDLINE
...
LILACS
LIS